Results 121 to 130 of about 34,440,044 (184)

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
doaj   +1 more source

Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review. [PDF]

Obes Rev
Au HCT, Zheng YJ, Le GH, Wong S, Teopiz KM, Kwan ATH, Rosenblat JD, Mansur RB, Choi H, McIntyre RS.   +9 more
europepmc   +1 more source

WITHDRAWN: Can glucagon like peptide-1 receptor agonists be beneficial for brain health?

Ballabio G, Mason A, Paz V, Dale C, Sofat R, Garfield V.   +5 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes. [PDF]

Diabetes Ther
Panou T, Gouveri E, Popovic DS, Papazoglou D, Papanas N.   +4 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists as a Potential Mitochondrial Modulation Therapy for Hidradenitis Suppurativa. [PDF]

Acta Derm Venereol
Hosseini A, Von Gunten S, Hunger RE, Zouboulis CC, Seyed Jafari SM.   +4 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonists in India: Psychiatric considerations and the case for integrated metabo-psychiatry care. [PDF]

Indian J Psychiatry
Alam A.
europepmc   +1 more source

Readability of AI-Generated Patient Information on Glucagon-Like Peptide-1 Receptor Agonists. [PDF]

JMIR Bioinform Biotechnol
Williams T, Bilic-Curcic I, Hurley J, Mummareddy H, Cigrovski Berkovic M, Canecki Varzic S, Gradiser M.   +6 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonists for primary cardiovascular disease prevention in type 2 diabetes, a systematic review. [PDF]

BMJ Open Diabetes Res Care
Grenet G, Eskandari R, Ko J, Adams SP, Salzwedel DM, Heran BS, Ambasta A, Bassett K, Thompson W.   +8 more
europepmc   +1 more source